Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Q4 2023 Earnings Conference Call February 28, 2024 8:00 AM ET

Company Participants

Rob Barrow - Chief Executive Officer

Schond Greenway - Chief Financial Officer

Conference Call Participants

Brian Abrahams - RBC Capital Markets

Charles Duncan - Cantor Fitzgerald

Francois Brisebois - Oppenheimer

Sumant Kulkarni - Canaccord Genuity

Elemer Piros - Rodman & Renshaw

Operator

Good morning, and welcome to the Mind Medicine Full Year 2023 Financial Results and Corporate Update Conference Call. Currently all participants are in listen-only mode. This call is being webcast live on the Investors and Media section of MindMed's website at mindmed.co. And a recording will be available after the call.

For opening remarks, I would like to introduce Rob Barrow, CEO of MindMed. Please go ahead.

Rob Barrow

Thank you and good morning, everyone. Welcome to our full year 2023 financial results and corporate update conference call. The press release reporting our financial results is available in the Investors and Media section of our website, and our annual report on Form 10-K for the year ended December 31, 2023, is being filed today with the Securities and Exchange Commission.

During today's call, we will be making certain forward-looking statements, including, without limitation, statements about the potential safety, efficacy, and regulatory and clinical progress of our product candidates, our anticipated cash runway, and our future expectations, plans, partnerships, and prospects. These statements are subject to various risks, such as changes in market conditions and difficulties associated with research and development and regulatory approval processes that are described in the filings made with the SEC, including our annual report on Form 10-K being filed today.

Forward-looking statements are based on the assumptions, opinions, and estimates of management at the date the statements are made, including the non-occurrence of the risks and uncertainties that are described in the filings made with the SEC or other significant events occurring outside of MindMed's normal course of business. You are cautioned not to place undue reliance on these forward-looking statements, which are made as of today, February 28, 2024. MindMed disclaims any obligation to update such statements, even if management's views change, except as required by law.

Joining me on today's call are Schond Greenway, our Chief Financial Officer; and Dr. Daniel Karlin, our Chief Medical Officer.

We are excited to be providing this financial and business update during this important period for MindMed. 2023 was a highly productive year for MindMed, which included with positive Phase 2b results for MM120 in the treatment of patients with Generalized Anxiety Disorder, or GAD. We believe that the initial data we shared validates our scientific understanding of MM120's mechanism of action and shows the potential for an emerging best-in-class product profile compared to today's standard of care.